RGS inhibition at Gαi2selectively potentiates 5-HT1A–mediated antidepressant effects
- 2 June 2010
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (24) , 11086-11091
Abstract
Elevating serotonin (5-HT) levels with selective serotonin reuptake inhibitors (SSRIs) is the most widely used treatment for depression. However, current therapies are ineffective, have delayed benefit, or cause side effects in many patients. Here, we define a mechanism downstream of 5-HT1A receptors that mediates antidepressant-like behavior and is profoundly and selectively enhanced by genetic disruption of regulators of G protein signaling (RGS) activity at Gαi2. Animals rendered insensitive to RGS protein regulation through a mutation in Gαi2 (G184S) exhibited spontaneous antidepressant- and anxiolytic-like behaviors. Mice expressing RGS-insensitive Gαi2 also exhibited increased cortical and hippocampal phosphorylation of glycogen synthase kinase-3β, a constitutively active proapoptotic kinase that is inhibited through phosphorylation in response to serotonin, SSRIs, and 5-HT1 receptor agonists. Both behavioral and biochemical phenotypes were blocked by treatment with WAY 100635, a 5-HT1A–selective antagonist. RGS-insensitive mice were also 5–10 times more responsive to the antidepressant-like effects of the SSRI fluvoxamine and 5-HT1A–selective agonist 8-hydroxy-2-dipropylaminotetralin. In contrast, the antidepressant potency of agents acting through nonserotonergic mechanisms was unchanged as was 5-HT1A action on body temperature. The findings point to a critical role for endogenous RGS proteins to suppress the antidepressant-like effects of 5-HT1A receptor activation. By selectively enhancing the beneficial effects of serotonin, inhibition of RGS proteins represents a therapeutic approach for the treatment of mood disorders.Keywords
This publication has 44 references indexed in Scilit:
- Differential modulation of mu‐opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Gα subtype dependentJournal of Neurochemistry, 2010
- 5-HT1A Autoreceptor Levels Determine Vulnerability to Stress and Response to AntidepressantsNeuron, 2010
- Role of GSK3β in behavioral abnormalities induced by serotonin deficiencyProceedings of the National Academy of Sciences, 2008
- Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorderCurrent Opinion in Pharmacology, 2007
- Identification of Small-Molecule Inhibitors of RGS4 Using a High-Throughput Flow Cytometry Protein Interaction AssayMolecular Pharmacology, 2007
- Pleiotropic Phenotype of a Genomic Knock-In of an RGS-Insensitive G184S Gnai2 AlleleMolecular and Cellular Biology, 2006
- Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugsInternational Journal of Neuropsychopharmacology, 2006
- The ascent of mouse: advances in modelling human depression and anxietyNature Reviews Drug Discovery, 2005
- Endogenous RGS Protein Action Modulates μ-Opioid Signaling through GαoJournal of Biological Chemistry, 2003
- A Point Mutation in Gαo and Gαi1Blocks Interaction with Regulator of G Protein Signaling ProteinsJournal of Biological Chemistry, 1998